Effects of Polyene phosphatidylcholine combined with Tenofovir in treatment of patients with chronic hepatitis B cirrhosis
Objective:To observe effects of Polyene phosphatidylcholine combined with Tenofovir in treatment of patients with chronic hepatitis B cirrhosis.Methods:A prospective study was conducted on 95 patients with chronic hepatitis B cirrhosis admitted to this hospital from February 2021 to February 2023.According to the random number table method,they were divided into control group(n=47)and observation group(n=48).The control group was treated with Tenofovir disoproxil fumarate tablets,while the observation group was treated with Polyene phosphatidylcholine capsules on the basis of that of the control group.Both groups were treated for 3 months.The negative rate of hepatitis B virus(HBV)-DNA,the levels of liver function indexes[alanine aminotransferase(ALT),aspartate aminotransferase(AST),total bilirubin(TBIL)],the liver fibrosis indexes[hyaluronic acid(HA),laminin(LN),type Ⅳ collagen(Ⅳ-C),type Ⅲ procollagen(PCⅢ)]and the T cell subsets indexes(CD3+,CD4+,CD8+,CD4+/CD8+),and the incidence of adverse reactions were compared between the two groups before and 3 months after the treatment.Results:After 2 and 3 months of treatment,the negative conversion rates of HBV-DNA in the observation group were higher than those in the control group,and the differences were statistically significant(P<0.05).After the treatment,the levels of ALT,AST,TBIL,HA,LN,IV-C and PCⅢ in the two groups were lower than those before the treatment,those in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).After the treatment,the levels of CD3+,CD4+ and CD4+/CD8+ in the two groups were higher than those before the treatment,and those in the observation group were higher than those in the control group;the levels of CD8+ in the two groups were lower than those before the treatment,and that in the observation group was lower than that in the control group;and the differences were statistically significant(P<0.05).However,there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions:Polyene phosphatidylcholine combined with Tenofovir in the treatment of the patients with chronic hepatitis B cirrhosis can increase the negative rate of HBV-DNA,reduce the levels of liver function indexes and liver fibrosis indexes,and improve the levels of T cell subsets indexes.Moreover,it is superior to single Tenofovir treatment.
Chronic hepatitis BLiver cirrhosisTenofovirPolyene phosphatidylcholineLiver fibrosisLiver functionT cell subset
万方数据
维普
